This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ambesi, A. Articles by McKeown-Longo, P. J. Search for Related Content PubMed PubMed Citation Articles by Ambesi, A. Articles by McKeown-Longo, P. J.

Anastellin, a Fragment of the First Type III Repeat of Fibronectin, Inhibits Extracellular Signal-Regulated Kinase and Causes G₁ Arrest in Human Microvessel Endothelial Cells

Center for Cell Biology and Cancer Research, Albany Medical College, Albany, New York

Requests for reprints: Paula J. McKeown-Longo, Center for Cell Biology and Cancer Research, MC-165, Albany Medical College, 47 New Scotland Avenue, Albany, NY 12208. Phone: 518-262-5666; Fax: 518-262-5669; E-mail: mckeowp{at}mail.amc.edu.

The formation of a microvascular endothelium plays a critical role in the growth and metastasis of established tumors. The ability of a fragment from the first type III repeat of fibronectin (III_1C), anastellin, to suppress tumor growth and metastasis in vivo has been reported to be related to its antiangiogenic properties, however, the mechanism of action of anastellin remains unknown. Utilizing cultures of human dermal microvascular endothelial cells, we provide evidence that anastellin inhibits signaling pathways which regulate the extracellular signal-regulated (ERK) mitogen-activated protein kinase pathway and subsequent expression of cell cycle regulatory proteins. Addition of anastellin to primary microvascular endothelial cells resulted in a complete inhibition of serum-dependent proliferation. Growth inhibition correlated with a decrease in serum-dependent expression of cyclin D1, cyclin A and the cyclin-dependent kinase, cdk4, key regulators of cell cycle progression through G₁ phase. Consistent with a block in G₁-S transition, anastellin inhibited serum-dependent incorporation of [³H]-thymidine into S-phase nuclei. Addition of anastellin to serum-starved microvessel cells resulted in a time-dependent and dose-dependent decrease in basal levels of phosphorylated MEK/ERK and blocked serum-dependent activation of ERK. Adenoviral infection with Ad.B-Raf:ER, an inducible estrogen receptor-B-Raf fusion protein, restored levels of active ERK in anastellin-treated cells, rescued levels of cyclin D1, cyclin A, and cdk4, and rescued [³H]-thymidine incorporation. These data suggest that the antiangiogenic properties of anastellin observed in mouse models of human cancer may be due to its ability to block endothelial cell proliferation by modulating ERK signaling pathways and down-regulating cell cycle regulatory gene expression required for G₁-S phase progression.

Key Words: fibronectin • angiogenesis • cell growth • adhesion • ERK

This article has been cited by other articles:

				J. Masuda, R. Usui, and Y. Maru Fibronectin Type I Repeat Is a Nonactivating Ligand for EphA1 and Inhibits ATF3-dependent Angiogenesis J. Biol. Chem., May 9, 2008; 283(19): 13148 - 13155. [Abstract] [Full Text] [PDF]

				X. Zhou, R. G. Rowe, N. Hiraoka, J. P. George, D. Wirtz, D. F. Mosher, I. Virtanen, M. A. Chernousov, and S. J. Weiss Fibronectin fibrillogenesis regulates three-dimensional neovessel formation Genes & Dev., May 1, 2008; 22(9): 1231 - 1243. [Abstract] [Full Text] [PDF]

				T. Ohashi and H. P. Erickson Domain Unfolding Plays a Role in Superfibronectin Formation J. Biol. Chem., November 25, 2005; 280(47): 39143 - 39151. [Abstract] [Full Text] [PDF]